Navigation Links
UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
Date:9/1/2011

ANAHEIM, Calif., Sept. 1, 2011 /PRNewswire/ -- Please replace the release dated August 24, 2011 with the following updated version.  First graph, second and third sentences added and should read: The Company will provide attendees an updated investor presentation, which will be filed in a Form 8K with the SEC after the close of the U.S. financial markets on Friday, September 9, 2011.  This presentation will also be available at http://ir.questcor.com/sec.cfm.  Second graph, second and third sentences updated and should read: Don M. Bailey, President and Chief Executive Officer, and members of the executive management team are scheduled to provide an overview of the Company in an "unplugged" fireside chat and Q&A session on Wednesday, September 14, 2011 at 8:00 a.m. ET.  A live audio only webcast and subsequent archived replay of the discussion will be accessible at http://ir.questcor.com/events.cfm.

The full updated release reads:

Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September

Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that members of its executive management team will present at the following investor conferences in early September.  The Company will provide attendees an updated investor presentation, which will be filed in a Form 8K with the SEC after the close of the U.S. financial markets on Friday, September 9, 2011.  This presentation will also be available at http://ir.questcor.com/sec.cfm.

  • The Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York City.  Don M. Bailey, President and Chief Executive Officer, and members of the executive management team are scheduled to provide an overview of the Company in an "unplugged" fireside chat and Q&A session on Wednesday, September 14, 2011 at 8:00 a.m. ET.  A live audio only webcast and subsequent archived replay of the discussion will be accessible at http://ir.questcor.com/events.cfm.
  • UBS Global Life Sciences Conference at the Grand Hyatt in New York City.  Mr. Bailey is scheduled to present on Monday, September 19, 2011 at 10:30 a.m. ET.  A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
2. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
3. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
4. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
5. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
6. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
7. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
8. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
9. Questcor Pharmaceuticals Selects BDO USA as its Auditor
10. Questcor Reports 2010 Financial Results
11. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):